BioCentury
ARTICLE | Clinical News

Rituxan rituximab: Phase II data

October 20, 2008 7:00 AM UTC

In an open-label, U.S. Phase II trial in 30 untreated, high-risk CLL patients, Campath alemtuzumab and Rituxan combination therapy resulted in 27 responses (90%) at 2 months after completion of 4 wee...